Gapping up
In reaction to strong earnings/guidance: NUS +4.4%, (Nu Skin announces $210 mln investment from Ping An ZQ China Growth Opportunity Limited; anticipates Q2 revenue at the high end of, or slightly above, our previous guidance of $560 to $580 million), CTRP +3.2%
M&A news: QLGC +9.5% (QLogic to be acquired by Cavium for approximately $15.50 per share ), TA +1.6% (responds to media reports, confirming it received a non-binding letter from a private equity firm in December)
Select metals/mining stocks trading higher: HMY +4.4%, BTG +3.2%, SLW +2.7%, SSRI +2.5%, ABX +2.4%,IAG +2.3%, NEM +2.2%, GFI +2%, GDX +1.9%, PAAS +1.9%, AU +1.6%, GOLD +1.5%
In reaction to strong earnings/guidance: NUS +4.4%, (Nu Skin announces $210 mln investment from Ping An ZQ China Growth Opportunity Limited; anticipates Q2 revenue at the high end of, or slightly above, our previous guidance of $560 to $580 million), CTRP +3.2%
M&A news: QLGC +9.5% (QLogic to be acquired by Cavium for approximately $15.50 per share ), TA +1.6% (responds to media reports, confirming it received a non-binding letter from a private equity firm in December)
Select metals/mining stocks trading higher: HMY +4.4%, BTG +3.2%, SLW +2.7%, SSRI +2.5%, ABX +2.4%,IAG +2.3%, NEM +2.2%, GFI +2%, GDX +1.9%, PAAS +1.9%, AU +1.6%, GOLD +1.5%
Other news: PTX +37.8% (announces positive Phase IV results of Silenor vs Zolpidem head-to-head arousability study), RLYP +4.6% ( announces new patient starts, outpatient prescriptions and units sold to hospitals/other institutions for the full month of May 2016 for Veltassa), BXE +4% (acquires assets in its west central Alberta core Ferrier area; provide an update on its ongoing credit facility), DVN +2.6% (monetizes non-core midland assets for $858 mln; increasing 2016 capital program $200 mln; raising 2016 production outlook ), COVS +1.9% (Roumell (4.98% active stake) sends letter to Board), MRK +1.6% (EYNOTE-024 trial of KEYTRUDA in patients with previously untreated advanced non-small cell lung cancer whose tumors expressed high levels of PD-L1 met its primary endpoint)
Analyst comments: EXAS +6.1% (upgraded to Buy from Hold at Craig Hallum and raises tgt to $18 (new street high)), AMD +2% (upgraded to Buy at Canaccord Genuity), CENT +1.7% (upgraded to Buy at SunTrust), COMM+1.1% (initiated with a Buy at Credit Agricole)
Analyst comments: EXAS +6.1% (upgraded to Buy from Hold at Craig Hallum and raises tgt to $18 (new street high)), AMD +2% (upgraded to Buy at Canaccord Genuity), CENT +1.7% (upgraded to Buy at SunTrust), COMM+1.1% (initiated with a Buy at Credit Agricole)